Cytokinetics' Aficamten superior to metoprolol in HCM patients.

• Cytokinetics announced primary results from MAPLE-HCM trial • Aficamten superior to standard beta-blocker metoprolol • Positive trial results consistent across subgroups • Results presented at European Society of Cardiology Congress 2025 • Published in New England Journal of Medicine • Company to host investor event and webcast on September 2, 2025

Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced significant data from the MAPLE-HCM trial, which was presented at the European Society of Cardiology Congress 2025 in Madrid, Spain. The trial evaluated the effectiveness of aficamten, an investigational drug candidate, in patients with obstructive hypertrophic cardiomyopathy (oHCM). The primary results were also published in the Journal of the American College of Cardiology [1].

The MAPLE-HCM trial compared aficamten to the standard beta-blocker metoprolol. The data showed that aficamten was superior to metoprolol in improving cardiac structure and function. Specifically, aficamten demonstrated significant improvements in measures of diastolic function and reduced the likelihood of mitral valve systolic anterior motion (SAM) and mitral valve leaflet-septal contact, the primary contributor to left ventricular outflow tract (LVOT) obstruction. There was also a significant decrease in maximal wall thickness in patients treated with aficamten compared to those treated with metoprolol [2].

The trial also assessed the incidence of atrial fibrillation (AF) in patients treated with aficamten. Among 173 patients followed for at least 48 weeks, four patients developed new-onset AF, resulting in an incidence rate of 1.5% per year. This rate is consistent with expected rates from validated prediction models in patients with HCM and healthy individuals [3].

Cytokinetics will host an investor event and webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the primary results from MAPLE-HCM and other data presented at the European Society of Cardiology Congress 2025. Interested parties can register online at [4].

References:
[1] https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Presents-New-Data-Related-to-Aficamten-at-the-European-Society-of-Cardiology-Congress-2025/default.aspx
[2] https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Presents-New-Data-Related-to-Aficamten-at-the-European-Society-of-Cardiology-Congress-2025/default.aspx
[3] https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Presents-New-Data-Related-to-Aficamten-at-the-European-Society-of-Cardiology-Congress-2025/default.aspx
[4] https://cytokinetics-esc-2025.open-exchange.net/